Logo image
Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design
Journal article   Peer reviewed

Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design

Christopher R Butler, Jinlong Wang, Brian T O’Neill, Michael A Brodney, Elizabeth M Beck, Gabriela Barreiro, Charles E Nolan, Feng Pan, Felix Vajdos, Kevin Parris, …
Journal of medicinal chemistry, Vol.58(6), pp.2678-2702
03/26/2015
DOI: 10.1021/jm501833t
PMID: 25695670
url
https://doi.org/10.7270/q2w37z1dView
Open Access

Abstract

The identification of centrally efficacious β-secretase (BACE1) inhibitors for the treatment of Alzheimer’s disease (AD) has historically been thwarted by an inability to maintain alignment of potency, brain availability, and desired absorption, distribution, metabolism, and excretion (ADME) properties. In this paper, we describe a series of truncated, fused thioamidines that are efficiently selective in garnering BACE1 activity without simultaneously inhibiting the closely related cathepsin D or negatively impacting brain penetration and ADME alignment, as exemplified by 36. Upon oral administration, these inhibitors exhibit robust brain availability and are efficacious in lowering central Amyloid β (Aβ) levels in mouse and dog. In addition, chronic treatment in aged PS1/APP mice effects a decrease in the number and size of Aβ-derived plaques. Most importantly, evaluation of 36 in a 2-week exploratory toxicology study revealed no accumulation of autofluorescent material in retinal pigment epithelium or histology findings in the eye, issues observed with earlier BACE1 inhibitors.

Details

Metrics

Logo image